Browse the preliminary programme and build a personalised schedule for the congress.

Displaying One Session

Clinical Focus
Moderators
  • H. Klümpen (Amsterdam, NL)
  • M. Ronot (Clichy, FR)
EBIR
Yes
Date
Mon, Apr 8, 2019
Time
08:30 - 10:10

101.1 - HCC guidelines - what is new?

EBIR
Yes
Presenter:
  • M. Varela (Oviedo, ES)
Learning Objectives:
1. To describe recent updates in international guidelines for classification of HCC
2. To learn about validation of staging systems
3. To discuss the limitations of HCC classification systems in clinical practice

101.2 - Percutaneous ablation: best indication and which energy

EBIR
Yes
Presenter:
  • A. Hocquelet (Lausanne, CH)
Learning Objectives:
1. To learn about the different ablative techniques and approaches for HCC
2. To understand the advantages and disadvantages of each technology and the reported clinical data
3. To discuss the criteria for optimal patient selection

101.3 - Radioembolisation: who is a good candidate after the new classification

EBIR
Yes
Presenter:
  • J. Ricke (Munich, DE)
Learning Objectives:
1. To describe the results of radioembolisation in recent clinical trials
2. To understand the proposed changes in treatment algorithms
3. To discuss the criteria for optimal patient selection from an IR perspective

101.4 - Scientific paper

Presenter:
  • M. Ronot (Clichy, FR)

101.5 - Intermediate stage: what are the indications for combined IO therapies?

Presenter:
  • R. Lencioni (Pisa, IT)
Learning Objectives:
1. To describe the spectrum of clinical scenarios included in the intermediate stage
2. To understand the potential of offering cure to a subset of intermediate patients by using combined treatment approaches
3. To discuss the potential benefit of combining interventional therapies and novel systemic agents

101.6 - HCC and Immunotherapy

EBIR
Yes
Presenter:
  • H. Klümpen (Amsterdam, NL)
Learning Objectives:
1. To understand the basic concepts of immuno-oncology in the specific setting of HCC treatment
2. To discuss recent clinical data and the on-going investigation
3. To understand the future perspectives of immuno-oncology in the management of HCC